The European Commission (EC) has granted approval to Bristol Myers Squibb's (BMS) perioperative regimen of neoadjuvant Opdivo (nivolumab), combined with chemotherapy and followed by adjuvant Opdivo ...
Bristol Myers Squibb has won FDA approval for an injectable version of its blockbuster cancer immunotherapy Opdivo, a regulatory decision that gives patients a more convenient dosing option and ...
The pairing of two Bristol Myers Squibb immunotherapies is now permitted for the first-line treatment of two types of gastrointestinal cancers, after regulatory decisions handed out this past week ...
Approval based on results from the CheckMate-77T trial which showed perioperative Opdivo improved event-free survival compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant ...
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in Patients with Microsatellite ...
Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of its Cabometyx and Bristol Myers Squibb’s Opdivo and Yervoy in kidney cancer ...
The Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday accepted Bristol-Myers Squibb's Opdivo (nivolumab) to its early access to medicines scheme (EAMS) to treat relapsed or ...
Bristol Myers Squibb (BMS) will partner with Hengrui Pharma to co-develop 13 early-stage programs in oncology, hematology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results